785 related articles for article (PubMed ID: 27004496)
1. Impact of Drug-Eluting Stent Implantation for Femoropopliteal In-Stent Occlusion.
Tomoi Y; Soga Y; Iida O; Shiraki T; Kobayashi Y; Hiramori S; Ando K
J Endovasc Ther; 2016 Jun; 23(3):461-7. PubMed ID: 27004496
[TBL] [Abstract][Full Text] [Related]
2. Drug-Eluting Stent vs Percutaneous Transluminal Angioplasty for Treatment of Femoropopliteal In-Stent Restenosis: Results From a Retrospective 1-Year Multicenter Study.
Murata N; Takahara M; Soga Y; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Yokoi H; Tosaka A; Tanaka N; Iida O
J Endovasc Ther; 2016 Aug; 23(4):642-7. PubMed ID: 27099284
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel-Eluting Balloon vs Standard Angioplasty to Reduce Restenosis in Diabetic Patients With In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Arteries: Three-Year Results of the DEBATE-ISR Study.
Grotti S; Liistro F; Angioli P; Ducci K; Falsini G; Porto I; Ricci L; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
J Endovasc Ther; 2016 Feb; 23(1):52-7. PubMed ID: 26511896
[TBL] [Abstract][Full Text] [Related]
4. Intravascular Ultrasound-Derived Stent Dimensions as Predictors of Angiographic Restenosis Following Nitinol Stent Implantation in the Superficial Femoral Artery.
Miki K; Fujii K; Kawasaki D; Shibuya M; Fukunaga M; Imanaka T; Tamaru H; Sumiyoshi A; Nishimura M; Horimatsu T; Saita T; Okada K; Kimura T; Honda Y; Fitzgerald PJ; Masuyama T; Ishihara M
J Endovasc Ther; 2016 Jun; 23(3):424-32. PubMed ID: 27044270
[TBL] [Abstract][Full Text] [Related]
5. Impact of Cilostazol Administration on Femoropopliteal In-Stent Restenosis.
Tomoi Y; Soga Y; Iida O; Fujihara M; Ando K
J Endovasc Ther; 2017 Oct; 24(5):640-646. PubMed ID: 28675951
[TBL] [Abstract][Full Text] [Related]
6. Drug-coated balloons vs. drug-eluting stents for treatment of long femoropopliteal lesions.
Zeller T; Rastan A; Macharzina R; Tepe G; Kaspar M; Chavarria J; Beschorner U; Schwarzwälder U; Schwarz T; Noory E
J Endovasc Ther; 2014 Jun; 21(3):359-68. PubMed ID: 24915582
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes of balloon angioplasty alone versus nitinol stent implantation in patients with small femoropopliteal artery disease: Observations from the Retrospective Multicenter Analysis for Femoropopliteal Stenting (REAL-FP).
Kamioka N; Soga Y; Kuramitsu S; Iida O; Hirano K; Suzuki K; Kawasaki D; Yamaoka T; Suematsu N; Shintani Y; Miyashita Y; Takahashi H; Tsuchiya T; Shinozaki N; Okazaki S; Ando K
Catheter Cardiovasc Interv; 2017 Nov; 90(5):790-797. PubMed ID: 28722294
[TBL] [Abstract][Full Text] [Related]
8. Mid-term clinical outcome and predictors of vessel patency after femoropopliteal stenting with self-expandable nitinol stent.
Soga Y; Iida O; Hirano K; Yokoi H; Nanto S; Nobuyoshi M
J Vasc Surg; 2010 Sep; 52(3):608-15. PubMed ID: 20573476
[TBL] [Abstract][Full Text] [Related]
9. The Characteristics of In-Stent Restenosis After Drug-Eluting Stent Implantation in Femoropopliteal Lesions and 1-Year Prognosis After Repeat Endovascular Therapy for These Lesions.
Iida O; Takahara M; Soga Y; Hirano K; Yamauchi Y; Zen K; Kawasaki D; Nanto S; Yokoi H; Uematsu M;
JACC Cardiovasc Interv; 2016 Apr; 9(8):828-834. PubMed ID: 27101908
[TBL] [Abstract][Full Text] [Related]
10. Intravascular ultrasound measurements after drug-eluting stent placement in femoropopliteal lesions: determining predictors of restenosis.
Mori S; Hirano K; Nakano M; Muramatsu T; Tsukahara R; Ito Y; Ishimori H
J Endovasc Ther; 2015 Jun; 22(3):341-9. PubMed ID: 25862363
[TBL] [Abstract][Full Text] [Related]
11. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled study of excimer laser atherectomy for treatment of femoropopliteal in-stent restenosis: initial results from the EXCITE ISR trial (EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis).
Dippel EJ; Makam P; Kovach R; George JC; Patlola R; Metzger DC; Mena-Hurtado C; Beasley R; Soukas P; Colon-Hernandez PJ; Stark MA; Walker C;
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt A):92-101. PubMed ID: 25499305
[TBL] [Abstract][Full Text] [Related]
13. Laser Atherectomy Combined With Drug-Coated Balloon Angioplasty Is Associated With Improved 1-Year Outcomes for Treatment of Femoropopliteal In-Stent Restenosis.
Kokkinidis DG; Hossain P; Jawaid O; Alvandi B; Foley TR; Singh GD; Waldo SW; Laird JR; Armstrong EJ
J Endovasc Ther; 2018 Feb; 25(1):81-88. PubMed ID: 29219030
[TBL] [Abstract][Full Text] [Related]
14. Paclitaxel-Eluting Balloon Versus Standard Balloon Angioplasty in In-Stent Restenosis of the Superficial Femoral and Proximal Popliteal Artery: 1-Year Results of the PACUBA Trial.
Kinstner CM; Lammer J; Willfort-Ehringer A; Matzek W; Gschwandtner M; Javor D; Funovics M; Schoder M; Koppensteiner R; Loewe C; Ristl R; Wolf F
JACC Cardiovasc Interv; 2016 Jul; 9(13):1386-92. PubMed ID: 27388828
[TBL] [Abstract][Full Text] [Related]
15. Propensity Score Analysis Comparing Clinical Outcomes of Drug-Eluting vs Bare Nitinol Stents in Femoropopliteal Lesions.
Soga Y; Takahara M; Iida O; Nakano M; Yamauchi Y; Zen K; Kawasaki D; Ando K
J Endovasc Ther; 2016 Feb; 23(1):33-9. PubMed ID: 26763256
[TBL] [Abstract][Full Text] [Related]
16. Preoperative inflammatory status as a predictor of primary patency after femoropopliteal stent implantation.
Nakazawa KR; Wengerter SP; Power JR; Lookstein RA; Tadros RO; Ting W; Faries PL; Vouyouka AG
J Vasc Surg; 2017 Jul; 66(1):151-159. PubMed ID: 28259571
[TBL] [Abstract][Full Text] [Related]
17. Drug-eluting balloon in peripheral intervention for the superficial femoral artery: the DEBATE-SFA randomized trial (drug eluting balloon in peripheral intervention for the superficial femoral artery).
Liistro F; Grotti S; Porto I; Angioli P; Ricci L; Ducci K; Falsini G; Ventoruzzo G; Turini F; Bellandi G; Bolognese L
JACC Cardiovasc Interv; 2013 Dec; 6(12):1295-302. PubMed ID: 24239203
[TBL] [Abstract][Full Text] [Related]
18. Impact of IVUS-Derived Vessel Size on Midterm Outcomes After Stent Implantation in Femoropopliteal Lesions.
Miki K; Fujii K; Tanaka T; Yanaka K; Yoshihara N; Nishimura M; Sumiyoshi A; Horimatsu T; Imanaka T; Fukunaga M; Akahori H; Masuyama T; Ishihara M
J Endovasc Ther; 2020 Feb; 27(1):77-85. PubMed ID: 31948376
[No Abstract] [Full Text] [Related]
19. Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
Vent PA; Kaladji A; Davaine JM; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
Ann Vasc Surg; 2017 Aug; 43():166-175. PubMed ID: 28300676
[TBL] [Abstract][Full Text] [Related]
20. Classification and clinical impact of restenosis after femoropopliteal stenting.
Tosaka A; Soga Y; Iida O; Ishihara T; Hirano K; Suzuki K; Yokoi H; Nanto S; Nobuyoshi M
J Am Coll Cardiol; 2012 Jan; 59(1):16-23. PubMed ID: 22192663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
